Fundsmith Reduces $79M in Catalyst Pharmaceuticals Inc ($CPRX)
Key Points
- Fundsmith changed its Catalyst Pharmaceuticals Inc ($CPRX) stake by 74.88% last quarter, cutting to 844,887 shares worth $26.50 million.
- $CPRX last traded around $31.36.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Fundsmith reduced its position in Catalyst Pharmaceuticals Inc ($CPRX) by 74.88% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 844,887 shares of Catalyst Pharmaceuticals Inc after selling 2,518,920 shares during the quarter. Fundsmith's holdings in Catalyst Pharmaceuticals Inc were worth $26.50 million as of its most recent filing.
Catalyst Pharmaceuticals Inc Stock Price
Shares of Catalyst Pharmaceuticals Inc ($CPRX) traded around $31.36 on Saturday.
Catalyst Pharmaceuticals Inc Earnings
Analysts Set New Price Targets
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Get Catalyst Pharmaceuticals Inc alerts
New 13F filings, insider trades, and analyst moves on $CPRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.